Office-based vergence and anti-suppression therapy for the treatment of small-to-moderate angle intermittent exotropia: A randomised clinical trial.
Martin Ming-Leung MaYing KangMitchell M ScheimanQiwen ChenXuelian YeLiuqing PanJiayu DengGuangxing SuGuohui ZhangXiang ChenPublished in: Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) (2023)
In this randomised clinical trial of participants aged 6 to <18 years with IXT, we found that the OBVAT group had a significantly better distance Office Control Score than the observation group at the 17-week visit. This study provides the first data from a randomised clinical trial demonstrating the effectiveness of OBVAT for improving the control of IXT. Eye care practitioners should consider OBVAT as a viable, non-surgical treatment option for IXT. A full-scale randomised clinical trial investigating the long-term effectiveness of OBVAT in treating IXT is warranted.
Keyphrases
- clinical trial
- open label
- double blind
- phase ii
- study protocol
- randomized controlled trial
- placebo controlled
- phase iii
- systematic review
- healthcare
- primary care
- high intensity
- palliative care
- high resolution
- electronic health record
- quality improvement
- machine learning
- pain management
- general practice
- combination therapy